Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Optimind (OMND) provides an update on Health Canada’s Dealer License under joint-venture with Manitari Pharma
  • Manitari Pharma has begun permitting and planning the build-out of its facility under the guidance of Health Canada
  • Health Canada has approved Manitari Pharma’s plan, pending final inspection, to install a Security Level 3 vault and grow rooms
  • Optimind offers psychedelic-assisted treatment to patients suffering from PTSD, anxiety, depression, and other mental illnesses.
  • Optimind Pharma Corp. (OMND) is in the grey, trading at C$0.14 at 11:23 am EST

Optimind Pharma (OMND) updated its joint venture with Manitari Pharma Corporation, which is 40 per cent owned by Optimind.

Manitari Pharma has begun permitting and planning the build-out of its facility by the guidance of Health Canada.

Health Canada has approved Manitari Pharma’s plan, pending final inspection, to install a Security Level 3 vault and grow rooms based on the Health Canada Directive on Physical Security Requirements for Controlled Substances and Drugs.

A Dealer’s License would permit Manitari Pharma to perform the following activities: procure controlled substances, including by import, synthesis, propagation, cultivation, and harvesting of psychedelic mushrooms for Psilocybin extraction and more.

“[…] Optimind looks forward to continuing working with Manitari Pharma as it develops treatments for qualifying patients that desperately need psychedelic-enhanced therapy to get better,” commented Tomas Sipos, Chief Executive Officer at Optimind.

“This is vital in expanding our mission in ensuring the future mental health of First Nations and the global community at large,” commented Anna Freeman, Chief Executive Officer at Manitari Pharma.

Optimind offers psychedelic-assisted treatment to patients suffering from PTSD, anxiety, depression, and other mental illnesses and disabilities by providing ketamine-assisted therapy and other psychedelic-enhanced psychotherapy modalities.

Optimind is an emerging provider of psychedelic therapies. 

Optimind Pharma Corp. (OMND) is in the grey, trading at C$0.14 at 11:23 am EST.


More From The Market Herald

" Revive Therapeutics (CSE:RVV) updates Bucillamine in treating COVID-19

Revive Therapeutics (RVV) announced an update of its Food and Drug Administration (FDA) phase three clinical trial for Bucillamine.
The Market Herald Video

" BioVaxys (CSE:BIOV) signs binding term sheet for distribution of Papilocare in the U.S.

BioVaxys Technology Corp. (BIOV) has signed a binding term sheet with Procare Health Iberia, S.L. of Barcelona, Spain.

" Satellos Bioscience (TSXV:MSCL) announces OTCQB listing

Common shares of Satellos Bioscience (MSCL) have commenced trading on the OTCQB Venture Market (OTCQB) under the symbol MSCLF.
Innocan Pharma - CEO Iris Bincovish

" Innocan Pharma (CSE:INNO) patent application for treatment of psoriasis of the scalp goes national

Innocan Pharma’s (INNO) patent application, which claims cannabinoid-based topical compositions can treat psoriasis of the scalp, has reached the national phase.